The trial is enrolling adult women with recurrent ovarian cancer after at least two previous therapies. Credit: Jo Panuwat D / Shutterstock.com. (Jo Panuwat D / Shutterstock.com.) Anixa Biosciences ...

Follicle-stimulating hormone (FSH) traditionally mediates gametogenesis via the FSH receptor (FSHR) on ovarian granulosa and testicular Sertoli cells. Recent evidence reveals FSHR expression beyond ...

Radionetics Oncology Inc. has discovered drugs targeting follicle-stimulating hormone (FSH) receptors reported to be useful for the diagnosis and treatment of cancer.

Follicle‐stimulating hormone (FSH) is central to the regulation of spermatogenesis, acting on Sertoli cells to promote germ‐cell maturation and support testicular function. While its therapeutic use ...

A phase I, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed/refractory CD19+ B-cell malignancies. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the first patient has been treated in ...

Phase 1 clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer (OVCA). This is an ...

Emerging and approved oral treatments are expanding options for women with symptomatic uterine leiomyomas, but long-term ...

Hormones play a crucial role in the overall health and well-being of women. These chemical messengers, produced by various glands in the body, regulate a multitude of processes, including metabolism, ...